Galectin Therapeutics INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Galectin Therapeutics reports 2025 annual results, highlighting mixed NAVIGATE trial outcomes for belapectin in MASH cirrhosis and ongoing financing needs.
NASDAQ
10-K: Galectin Therapeutics Reports NAVIGATE Trial Results, Outlines Future Strategy in Annual 10-K Filing
Galectin Therapeutics' 10-K filing details the NAVIGATE trial results, ongoing data analysis, financial position, and future strategies for its lead drug candidate, belapectin, in fibrotic diseases and cancer.
NASDAQ
Galectin Therapeutics extends warrant expiration dates and files its annual report, detailing financial results and strategic updates.